B
ABBV icon

Bridgeworth’s AbbVie ABBV Stock Holding History

Bridgeworth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$845K Sell
5,454
-50
-0.9% -$7.29K 0.08% 80
2023
Q3 		$820K Sell
5,504
-82
-1% -$12K 0.09% 75
2023
Q2 		$753K Sell
5,586
-342
-6% -$50.2K 0.08% 81
2023
Q1 		$945K Sell
5,928
-357
-6% -$54.6K 0.12% 79
2022
Q4 		$1.02M Hold
6,285
– – 0.16% 69
2022
Q3 		$844K Sell
6,285
-181
-3% -$26K 0.2% 67
2022
Q2 		$990K Sell
6,466
-20
-0.3% -$3.06K 0.23% 63
2022
Q1 		$1.05M Sell
6,486
-838
-11% -$122K 0.24% 60
2021
Q4 		$992K Buy
7,324
+1,493
+26% +$176K 0.22% 57
2021
Q3 		$629K Sell
5,831
-92
-2% -$10.5K 0.18% 69
2021
Q2 		$667K Sell
5,923
-267
-4% -$30.1K 0.19% 61
2021
Q1 		$670K Sell
6,190
-294
-5% -$31.4K 0.21% 57
2020
Q4 		$695K Buy
6,484
+1,192
+23% +$115K 0.23% 57
2020
Q3 		$464K Sell
5,292
-528
-9% -$49.7K 0.17% 74
2020
Q2 		$571K Sell
5,820
-200
-3% -$17.6K 0.22% 63
2020
Q1 		$459K Sell
6,020
-16
-0.3% -$1.36K 0.21% 67
2019
Q4 		$534K Sell
6,036
-391
-6% -$32.5K 0.2% 62
2019
Q3 		$487K Buy
6,427
+663
+12% +$45.5K 0.19% 65
2019
Q2 		$419K Buy
5,764
+241
+4% +$18.9K 0.16% 76
2019
Q1 		$445K Sell
5,523
-2,245
-29% -$184K 0.18% 72
2018
Q4 		$599K Sell
7,768
-14
-0.2% -$1.23K 0.34% 43
2018
Q3 		$620K Buy
7,782
+968
+14% +$91.8K 0.34% 42
2018
Q2 		$631K Sell
6,814
-1,043
-13% -$102K 0.27% 55
2018
Q1 		$716K Buy
+7,857
New +$863K 0.33% 53
2017
Q3 		– Sell
-10,402
Closed -$745K – 62
2017
Q2 		$745K Sell
10,402
-1,337
-11% -$89.9K 0.38% 50
2017
Q1 		$759K Buy
11,739
+5,740
+96% +$361K 0.4% 51
2016
Q4 		$368K Buy
+5,999
New +$366K 0.2% 80

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bridgeworth's ABBV Position: Q4 2023 in Review

Bridgeworth reduced its AbbVie (ABBV) stake by 0.91% in Q4 2023, selling an estimated $7.29K and leaving 5,454 shares worth $845K. The position accounts for 0.08% of the portfolio, ranked #80.

Bridgeworth first reported a position in ABBV in Q4 2016 and has held it in 27 quarters since. The position peaked at $1.05M in Q1 2022. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • Bridgeworth held 5,454 shares of AbbVie worth $845K as of Q4 2023.
  • Bridgeworth sold 50 AbbVie shares in Q4 2023, an estimated $7.29K.
  • AbbVie made up 0.08% of Bridgeworth's portfolio in Q4 2023, its #80 holding.
  • Bridgeworth first reported a position in AbbVie in Q4 2016 and has held it in 27 quarters since.
  • Bridgeworth's AbbVie position peaked at $1.05M in Q1 2022.
  • 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Bridgeworth's 13F filing for Q4 2023, filed 26 Jan 2024.